Spyre Therapeutics Ownership 2024 | Who Owns Spyre Therapeutics Now?
Institutional Ownership
0.33%
Insider Ownership
2.40%
Retail Ownership
97.26%
Institutional Holders
3.00
Spyre Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VR ADVISER, LLC | - | - | - | -295,034 | -100.00% | - | Dec 31, 2023 |
| IFP ADVISORS, INC | - | - | - | -2,860 | -100.00% | - | Dec 31, 2023 |
| YU FAN | - | - | - | -20,592 | -100.00% | - | Dec 31, 2023 |
Spyre Therapeutics's largest institutional shareholder is VR ADVISER, LLC, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VR ADVISER, LLC | - | - | - | -295,034 | -100.00% | - | Dec 31, 2023 |
| IFP ADVISORS, INC | - | - | - | -2,860 | -100.00% | - | Dec 31, 2023 |
| YU FAN | - | - | - | -20,592 | -100.00% | - | Dec 31, 2023 |
The largest Spyre Therapeutics shareholder by % of total assets is VR ADVISER, LLC. The company owns 0.00 shares of Spyre Therapeutics (AGLE), representing 0.00% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| IFP ADVISORS, INC | - | - | - | -2,860 | -100.00% | - | Dec 31, 2023 |
| YU FAN | - | - | - | -20,592 | -100.00% | - | Dec 31, 2023 |
| VR ADVISER, LLC | - | - | - | -295,034 | -100.00% | - | Dec 31, 2023 |
As of Dec 31 2023, Spyre Therapeutics's largest institutional buyer is IFP ADVISORS, INC. The company purchased -2.86K stocks of AGLE, valued at -.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VR ADVISER, LLC | - | - | - | -295,034 | -100.00% | - | Dec 31, 2023 |
| YU FAN | - | - | - | -20,592 | -100.00% | - | Dec 31, 2023 |
| IFP ADVISORS, INC | - | - | - | -2,860 | -100.00% | - | Dec 31, 2023 |
As of Dec 31 2023, Spyre Therapeutics's biggest institutional seller is VR ADVISER, LLC. The company sold -0.30M shares of AGLE, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VR ADVISER, LLC | - | - | - | -295,034 | -100.00% | - | Dec 31, 2023 |
| YU FAN | - | - | - | -20,592 | -100.00% | - | Dec 31, 2023 |
| IFP ADVISORS, INC | - | - | - | -2,860 | -100.00% | - | Dec 31, 2023 |
Spyre Therapeutics's largest sold out institutional shareholder by shares sold is VR ADVISER, LLC, sold -0.30M shares, valued at -, as of undefined.
Spyre Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| VANGUARD VALLEY FORGE FUNDS | 0.07% | 33,281 | - | - | Dec 31, 2023 |
| BRIDGEWAY FUNDS INC | 0.06% | 150,000 | - | - | Dec 29, 2023 |
| FIDELITY ADVISOR SERIES VII | 0.04% | 353,495 | 353,495 | - | Jan 31, 2024 |
| FORUM FUNDS II | 0.03% | 28,600 | - | - | Jan 31, 2024 |
| Vericimetry Funds | 0.02% | 2,360 | - | - | Dec 31, 2023 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.01% | 5,803 | - | - | Dec 31, 2023 |
| QUANTITATIVE MASTER SERIES LLC | 0.01% | 71,346 | - | - | Dec 31, 2023 |
| FIDELITY SECURITIES FUND | 0.01% | 671,695 | 671,695 | - | Jan 31, 2024 |
| FIDELITY CAPITAL TRUST | 0.01% | 62,004 | 62,004 | - | Jan 31, 2024 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.01% | 1,277 | - | - | Dec 31, 2023 |
| DRIEHAUS MUTUAL FUNDS | 0.00% | 33,863 | - | - | Dec 29, 2023 |
| ALPS ETF Trust | 0.00% | 47,792 | - | - | Feb 29, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 106,810 | - | - | Feb 29, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 552,929 | - | - | Feb 29, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 3,710 | - | - | Dec 31, 2023 |
| VANGUARD INDEX FUNDS | 0.00% | 632,341 | - | - | Dec 31, 2023 |
| GOLDMAN SACHS VARIABLE INSURANCE TRUST | 0.00% | 5,237 | - | - | Dec 31, 2023 |
| VANGUARD QUANTITATIVE FUNDS | 0.00% | 11,700 | - | - | Dec 31, 2023 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 34,242 | - | - | Dec 31, 2023 |
| Brinker Capital Destinations Trust | 0.00% | 48,359 | - | - | Feb 29, 2024 |
| SunAmerica Specialty Series | 0.00% | 346 | - | - | Apr 30, 2021 |
| TIAA-CREF LIFE FUNDS | 0.00% | 1,425 | - | - | Dec 31, 2023 |
| PRUDENTIAL INVESTMENT PORTFOLIOS, INC. | 0.00% | 4,715 | - | - | Dec 29, 2023 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 15,466 | - | - | Dec 31, 2023 |
| AdvisorShares Trust | 0.00% | 1,157 | - | - | Dec 29, 2023 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 1,275 | - | - | Dec 31, 2023 |
| GPS Funds I | 0.00% | 1,397 | - | - | Dec 31, 2023 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 243,231 | - | - | Jan 31, 2024 |
| ALLSPRING MASTER TRUST | 0.00% | 12,074 | - | - | Feb 29, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 77,636 | 45,187 | 139.26% | Dec 31, 2023 |
| RBB FUND, INC. | 0.00% | 15,646 | - | - | Feb 29, 2024 |
| PACE SELECT ADVISORS TRUST | 0.00% | 49,384 | - | - | Jan 31, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 20,202 | - | - | Dec 31, 2023 |
| FIDELITY SALEM STREET TRUST | 0.00% | 290,838 | - | - | Feb 29, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 1,556 | - | - | Dec 31, 2023 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 10,100 | - | - | Dec 31, 2023 |
| ProFunds | 0.00% | 867 | - | - | Jan 31, 2024 |
| RYDEX SERIES FUNDS | 0.00% | 386 | - | - | Dec 31, 2023 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 1,378 | - | - | Feb 29, 2024 |
| Dimensional ETF Trust | 0.00% | 32,664 | - | - | Jan 31, 2024 |
| ALLIANZ VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 3,984 | - | - | Dec 31, 2023 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 138,178 | - | - | Feb 29, 2024 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 66,026 | - | - | Dec 31, 2023 |
| PENN SERIES FUNDS INC | 0.00% | 1,500 | - | - | Dec 29, 2023 |
| RYDEX DYNAMIC FUNDS | 0.00% | 213 | - | - | Dec 31, 2023 |
| VALIC Co I | 0.00% | 14,979 | - | - | Feb 29, 2024 |
| PGIM ETF TRUST | 0.00% | 2,909 | - | - | Feb 29, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 240 | - | - | Feb 29, 2024 |
| RYDEX VARIABLE TRUST | 0.00% | 39 | - | - | Dec 31, 2023 |
| MUTUAL FUND SERIES TRUST | 0.00% | 110,000 | - | - | Dec 31, 2023 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 4,308 | - | - | Jan 31, 2024 |
| Legg Mason Global Asset Management Trust | 0.00% | 30,064 | - | - | Jan 31, 2024 |
| SEI INSTITUTIONAL MANAGED TRUST | 0.00% | 78,313 | - | - | Dec 31, 2023 |
| RUSSELL INVESTMENT CO | 0.00% | 7,258 | - | - | Jan 31, 2024 |
| RUSSELL INVESTMENT FUNDS | 0.00% | 1,531 | - | - | Dec 31, 2023 |
| NORTHERN FUNDS | 0.00% | 19,998 | - | - | Dec 29, 2023 |
| HC CAPITAL TRUST | 0.00% | 652 | - | - | Dec 31, 2023 |
| PROSHARES TRUST | 0.00% | 5,145 | - | - | Feb 29, 2024 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 2,578 | 2,578 | - | Jan 31, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 1,772 | - | - | Feb 29, 2024 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 36,100 | - | - | Dec 31, 2023 |
| iShares U.S. ETF Trust | 0.00% | 1,431 | - | - | Jan 31, 2024 |
| Dimensional ETF Trust | 0.00% | 3,762 | - | - | Jan 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 8,492 | - | - | Dec 31, 2023 |
| Brighthouse Funds Trust II | 0.00% | 15,353 | - | - | Dec 31, 2023 |
| PACIFIC SELECT FUND | 0.00% | 20,364 | - | - | Dec 31, 2023 |
| SUNAMERICA SERIES TRUST | 0.00% | 1,300 | - | - | Jan 31, 2024 |
| SUNAMERICA SERIES TRUST | 0.00% | 1,300 | - | - | Jan 31, 2024 |
| Advisors' Inner Circle Fund III | 0.00% | 53 | - | - | Jan 31, 2024 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 3,519 | - | - | Dec 31, 2023 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 340 | - | - | Feb 29, 2024 |
| Bridge Builder Trust | 0.00% | 14,836 | - | - | Dec 31, 2023 |
| iSHARES TRUST | 0.00% | 33,740 | - | - | Feb 29, 2024 |
| Meeder Funds | 0.00% | 8 | - | - | Mar 31, 2024 |
| Legg Mason Global Asset Management Trust | 0.00% | 1,202 | - | - | Jan 31, 2024 |
| BlackRock Variable Series Funds, Inc. | 0.00% | 5,227 | - | - | Dec 31, 2023 |
| BLACKROCK FUNDS | 0.00% | 4,956 | - | - | Feb 29, 2024 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 0.00% | 9,300 | - | - | Feb 29, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 903 | - | - | Dec 31, 2023 |
| PRINCIPAL FUNDS, INC. | 0.00% | 2,570 | - | - | Feb 29, 2024 |
| John Hancock Funds II | 0.00% | 5,184 | - | - | Feb 29, 2024 |
Spyre Therapeutics's largest mutual fund holder by % of total assets is "VANGUARD VALLEY FORGE FUNDS", owning 33.28K shares, compromising 0.07% of its total assets.
Spyre Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Sep, 23 | 3 | -92.68% |
| 30 Jun, 23 | 41 | -2.38% |
| 31 Mar, 23 | 42 | -12.50% |
| 31 Dec, 22 | 48 | -4.00% |
| 30 Sep, 22 | 50 | -16.67% |
| 30 Jun, 22 | 60 | -24.05% |
| 31 Mar, 22 | 79 | -7.06% |
| 31 Dec, 21 | 85 | 13.33% |
| 30 Sep, 21 | 75 | -3.85% |
| 30 Jun, 21 | 78 | -8.24% |
| 31 Mar, 21 | 85 | -4.49% |
| 31 Dec, 20 | 89 | -2.20% |
| 30 Sep, 20 | 91 | 5.81% |
| 30 Jun, 20 | 86 | 30.30% |
| 31 Mar, 20 | 66 | -2.94% |
| 31 Dec, 19 | 68 | - |
| 30 Sep, 19 | 68 | -8.11% |
| 30 Jun, 19 | 74 | 5.71% |
| 31 Mar, 19 | 70 | 16.67% |
| 31 Dec, 18 | 60 | 1.69% |
| 30 Sep, 18 | 59 | -7.81% |
| 30 Jun, 18 | 64 | 68.42% |
| 31 Mar, 18 | 38 | 26.67% |
| 31 Dec, 17 | 30 | - |
| 30 Sep, 17 | 30 | - |
| 30 Jun, 17 | 30 | 36.36% |
| 31 Mar, 17 | 22 | -8.33% |
| 31 Dec, 16 | 24 | -11.11% |
| 30 Sep, 16 | 27 | 12.50% |
| 30 Jun, 16 | 24 | - |
As of 30 Sep 23, 3 institutions are holding Spyre Therapeutics's shares, representing a decrease of -92.68% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Sep, 23 | 318,486 | -99.55% |
| 30 Jun, 23 | 70,858,502 | 71.48% |
| 31 Mar, 23 | 41,322,333 | -3.03% |
| 31 Dec, 22 | 42,614,996 | -4.64% |
| 30 Sep, 22 | 44,687,126 | -9.42% |
| 30 Jun, 22 | 49,334,906 | 19.08% |
| 31 Mar, 22 | 41,430,905 | 3.87% |
| 31 Dec, 21 | 39,886,971 | -1.66% |
| 30 Sep, 21 | 40,562,121 | -1.22% |
| 30 Jun, 21 | 41,063,962 | -1.27% |
| 31 Mar, 21 | 41,590,338 | 0.36% |
| 31 Dec, 20 | 41,440,069 | 6.78% |
| 30 Sep, 20 | 38,807,887 | 2.11% |
| 30 Jun, 20 | 38,005,190 | 84.74% |
| 31 Mar, 20 | 20,572,593 | -0.41% |
| 31 Dec, 19 | 20,656,500 | 3.01% |
| 30 Sep, 19 | 20,053,277 | 0.25% |
| 30 Jun, 19 | 20,003,019 | 2.70% |
| 31 Mar, 19 | 19,477,890 | 18.80% |
| 31 Dec, 18 | 16,396,178 | 11.90% |
| 30 Sep, 18 | 14,652,115 | -0.25% |
| 30 Jun, 18 | 14,688,579 | 73.30% |
| 31 Mar, 18 | 8,476,047 | 6.96% |
| 31 Dec, 17 | 7,924,320 | 1.60% |
| 30 Sep, 17 | 7,799,820 | 0.74% |
| 30 Jun, 17 | 7,742,372 | 49.88% |
| 31 Mar, 17 | 5,165,816 | -7.75% |
| 31 Dec, 16 | 5,599,878 | -5.50% |
| 30 Sep, 16 | 5,925,679 | 7.18% |
| 30 Jun, 16 | 5,528,832 | - |
Spyre Therapeutics (AGLE) has 318.49K shares outstanding as of 30 Sep 23, down -99.55% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Sep, 23 | 0.33% | 0.01% |
| 30 Jun, 23 | 75.17% | 3.91% |
| 31 Mar, 23 | 43.84% | 1.71% |
| 31 Dec, 22 | 50.56% | 2.25% |
| 30 Sep, 22 | 47.44% | 1.32% |
| 30 Jun, 22 | 60.01% | 1.52% |
| 31 Mar, 22 | 62.78% | 1.71% |
| 31 Dec, 21 | 60.67% | 1.60% |
| 30 Sep, 21 | 61.65% | 1.57% |
| 30 Jun, 21 | 62.57% | 1.56% |
| 31 Mar, 21 | 63.40% | 1.05% |
| 31 Dec, 20 | 77.64% | 2.00% |
| 30 Sep, 20 | 62.35% | 1.21% |
| 30 Jun, 20 | 71.79% | 1.86% |
| 31 Mar, 20 | 62.16% | 1.49% |
| 31 Dec, 19 | 64.65% | 1.74% |
| 30 Sep, 19 | 60.96% | 1.64% |
| 30 Jun, 19 | 60.91% | 1.35% |
| 31 Mar, 19 | 67.14% | 1.08% |
| 31 Dec, 18 | 78.74% | 1.77% |
| 30 Sep, 18 | 66.64% | 1.31% |
| 30 Jun, 18 | 71.31% | 2.76% |
| 31 Mar, 18 | 50.84% | 1.85% |
| 31 Dec, 17 | 52.38% | 2.32% |
| 30 Sep, 17 | 47.53% | 1.58% |
| 30 Jun, 17 | 54.86% | 3.67% |
| 31 Mar, 17 | 38.65% | 1.18% |
| 31 Dec, 16 | 57.19% | 2.89% |
| 30 Sep, 16 | 44.47% | 2.02% |
| 30 Jun, 16 | 46.95% | - |
As of 30 Sep 23, Spyre Therapeutics is held by 0.33% institutional shareholders, representing a 0.01% growth compared to 30 Jun 23.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Sep, 23 | - | -100.00% |
| 30 Jun, 23 | 19 | 58.33% |
| 31 Mar, 23 | 12 | -42.86% |
| 31 Dec, 22 | 21 | 40.00% |
| 30 Sep, 22 | 15 | -50.00% |
| 30 Jun, 22 | 30 | -18.92% |
| 31 Mar, 22 | 37 | -17.78% |
| 31 Dec, 21 | 45 | 40.63% |
| 30 Sep, 21 | 32 | 3.23% |
| 30 Jun, 21 | 31 | 19.23% |
| 31 Mar, 21 | 26 | -39.53% |
| 31 Dec, 20 | 43 | 7.50% |
| 30 Sep, 20 | 40 | -41.18% |
| 30 Jun, 20 | 68 | 134.48% |
| 31 Mar, 20 | 29 | -3.33% |
| 31 Dec, 19 | 30 | 7.14% |
| 30 Sep, 19 | 28 | -42.86% |
| 30 Jun, 19 | 49 | 19.51% |
| 31 Mar, 19 | 41 | 46.43% |
| 31 Dec, 18 | 28 | -9.68% |
| 30 Sep, 18 | 31 | -42.59% |
| 30 Jun, 18 | 54 | 92.86% |
| 31 Mar, 18 | 28 | 86.67% |
| 31 Dec, 17 | 15 | 36.36% |
| 30 Sep, 17 | 11 | -31.25% |
| 30 Jun, 17 | 16 | 33.33% |
| 31 Mar, 17 | 12 | 20.00% |
| 31 Dec, 16 | 10 | -16.67% |
| 30 Sep, 16 | 12 | -50.00% |
| 30 Jun, 16 | 24 | - |
- institutional shareholders have increased their position in AGLE stock as of 30 Sep 23 compared to 19 in the previous quarter (a -100.00% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Sep, 23 | 2 | -75.00% |
| 30 Jun, 23 | 8 | -11.11% |
| 31 Mar, 23 | 9 | - |
| 31 Dec, 22 | 9 | -25.00% |
| 30 Sep, 22 | 12 | -20.00% |
| 30 Jun, 22 | 15 | -40.00% |
| 31 Mar, 22 | 25 | 13.64% |
| 31 Dec, 21 | 22 | -4.35% |
| 30 Sep, 21 | 23 | -14.81% |
| 30 Jun, 21 | 27 | -20.59% |
| 31 Mar, 21 | 34 | 30.77% |
| 31 Dec, 20 | 26 | -13.33% |
| 30 Sep, 20 | 30 | 150.00% |
| 30 Jun, 20 | 12 | -45.45% |
| 31 Mar, 20 | 22 | 29.41% |
| 31 Dec, 19 | 17 | -22.73% |
| 30 Sep, 19 | 22 | 175.00% |
| 30 Jun, 19 | 8 | -33.33% |
| 31 Mar, 19 | 12 | -25.00% |
| 31 Dec, 18 | 16 | -5.88% |
| 30 Sep, 18 | 17 | 325.00% |
| 30 Jun, 18 | 4 | - |
| 31 Mar, 18 | - | -100.00% |
| 31 Dec, 17 | 2 | -71.43% |
| 30 Sep, 17 | 7 | -12.50% |
| 30 Jun, 17 | 8 | 60.00% |
| 31 Mar, 17 | 5 | 25.00% |
| 31 Dec, 16 | 4 | -42.86% |
| 30 Sep, 16 | 7 | - |
| 30 Jun, 16 | - | - |
2 institutional shareholders have reduced their position in AGLE stock as of 30 Sep 23 compared to 8 in the previous quarter (a -75.00% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Sep, 23 | 3 | -92.68% | 318,486 | -99.55% | 0.33% | 0.01% | - | -100.00% | 2 | -75.00% |
| 30 Jun, 23 | 41 | -2.38% | 70,858,502 | 71.48% | 75.17% | 3.91% | 19 | 58.33% | 8 | -11.11% |
| 31 Mar, 23 | 42 | -12.50% | 41,322,333 | -3.03% | 43.84% | 1.71% | 12 | -42.86% | 9 | - |
| 31 Dec, 22 | 48 | -4.00% | 42,614,996 | -4.64% | 50.56% | 2.25% | 21 | 40.00% | 9 | -25.00% |
| 30 Sep, 22 | 50 | -16.67% | 44,687,126 | -9.42% | 47.44% | 1.32% | 15 | -50.00% | 12 | -20.00% |
| 30 Jun, 22 | 60 | -24.05% | 49,334,906 | 19.08% | 60.01% | 1.52% | 30 | -18.92% | 15 | -40.00% |
| 31 Mar, 22 | 79 | -7.06% | 41,430,905 | 3.87% | 62.78% | 1.71% | 37 | -17.78% | 25 | 13.64% |
| 31 Dec, 21 | 85 | 13.33% | 39,886,971 | -1.66% | 60.67% | 1.60% | 45 | 40.63% | 22 | -4.35% |
| 30 Sep, 21 | 75 | -3.85% | 40,562,121 | -1.22% | 61.65% | 1.57% | 32 | 3.23% | 23 | -14.81% |
| 30 Jun, 21 | 78 | -8.24% | 41,063,962 | -1.27% | 62.57% | 1.56% | 31 | 19.23% | 27 | -20.59% |
| 31 Mar, 21 | 85 | -4.49% | 41,590,338 | 0.36% | 63.40% | 1.05% | 26 | -39.53% | 34 | 30.77% |
| 31 Dec, 20 | 89 | -2.20% | 41,440,069 | 6.78% | 77.64% | 2.00% | 43 | 7.50% | 26 | -13.33% |
| 30 Sep, 20 | 91 | 5.81% | 38,807,887 | 2.11% | 62.35% | 1.21% | 40 | -41.18% | 30 | 150.00% |
| 30 Jun, 20 | 86 | 30.30% | 38,005,190 | 84.74% | 71.79% | 1.86% | 68 | 134.48% | 12 | -45.45% |
| 31 Mar, 20 | 66 | -2.94% | 20,572,593 | -0.41% | 62.16% | 1.49% | 29 | -3.33% | 22 | 29.41% |
| 31 Dec, 19 | 68 | - | 20,656,500 | 3.01% | 64.65% | 1.74% | 30 | 7.14% | 17 | -22.73% |
| 30 Sep, 19 | 68 | -8.11% | 20,053,277 | 0.25% | 60.96% | 1.64% | 28 | -42.86% | 22 | 175.00% |
| 30 Jun, 19 | 74 | 5.71% | 20,003,019 | 2.70% | 60.91% | 1.35% | 49 | 19.51% | 8 | -33.33% |
| 31 Mar, 19 | 70 | 16.67% | 19,477,890 | 18.80% | 67.14% | 1.08% | 41 | 46.43% | 12 | -25.00% |
| 31 Dec, 18 | 60 | 1.69% | 16,396,178 | 11.90% | 78.74% | 1.77% | 28 | -9.68% | 16 | -5.88% |
| 30 Sep, 18 | 59 | -7.81% | 14,652,115 | -0.25% | 66.64% | 1.31% | 31 | -42.59% | 17 | 325.00% |
| 30 Jun, 18 | 64 | 68.42% | 14,688,579 | 73.30% | 71.31% | 2.76% | 54 | 92.86% | 4 | - |
| 31 Mar, 18 | 38 | 26.67% | 8,476,047 | 6.96% | 50.84% | 1.85% | 28 | 86.67% | - | -100.00% |
| 31 Dec, 17 | 30 | - | 7,924,320 | 1.60% | 52.38% | 2.32% | 15 | 36.36% | 2 | -71.43% |
| 30 Sep, 17 | 30 | - | 7,799,820 | 0.74% | 47.53% | 1.58% | 11 | -31.25% | 7 | -12.50% |
| 30 Jun, 17 | 30 | 36.36% | 7,742,372 | 49.88% | 54.86% | 3.67% | 16 | 33.33% | 8 | 60.00% |
| 31 Mar, 17 | 22 | -8.33% | 5,165,816 | -7.75% | 38.65% | 1.18% | 12 | 20.00% | 5 | 25.00% |
| 31 Dec, 16 | 24 | -11.11% | 5,599,878 | -5.50% | 57.19% | 2.89% | 10 | -16.67% | 4 | -42.86% |
| 30 Sep, 16 | 27 | 12.50% | 5,925,679 | 7.18% | 44.47% | 2.02% | 12 | -50.00% | 7 | - |
| 30 Jun, 16 | 24 | - | 5,528,832 | - | 46.95% | - | 24 | - | - | - |
Spyre Therapeutics Insider Shareholders Trades
Open Market Insider Trades
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of Spyre Therapeutics's stock was made by Fairmount Funds Management LLC on Dec 29 2023, selling 3,435,480 shares at - per share (valued at -).
Spyre Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q4 2023 | 10 | 4 | 250.00% |
| Q3 2023 | 2 | - | - |
| Q2 2023 | 5 | 4 | 125.00% |
| Q1 2023 | 4 | - | - |
| Q4 2022 | 2 | 2 | 100.00% |
| Q3 2022 | 5 | 3 | 166.67% |
| Q2 2022 | 9 | - | - |
| Q1 2022 | 8 | - | - |
| Q4 2021 | 7 | - | - |
| Q3 2021 | 4 | - | - |
| Q2 2021 | 8 | - | - |
| Q1 2021 | 5 | 9 | 55.56% |
| Q4 2020 | 1 | - | - |
| Q2 2020 | 7 | - | - |
| Q1 2020 | 5 | - | - |
| Q4 2019 | 4 | 2 | 200.00% |
| Q2 2019 | 15 | - | - |
| Q1 2019 | 8 | 5 | 160.00% |
| Q4 2018 | 3 | 3 | 100.00% |
| Q3 2018 | 11 | 8 | 137.50% |
10 total buy trades, and 4 total sell trades (buy/sell ratio of 2.50%) were made by Spyre Therapeutics's insiders, as of Q4 2023.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q4 2023 | - | - | - |
| Q3 2023 | - | - | - |
| Q2 2023 | - | - | - |
| Q1 2023 | - | - | - |
| Q4 2022 | - | - | - |
| Q3 2022 | 1 | - | - |
| Q2 2022 | 1 | - | - |
| Q1 2022 | 3 | - | - |
| Q4 2021 | 6 | - | - |
| Q3 2021 | 3 | - | - |
| Q2 2021 | - | - | - |
| Q1 2021 | - | - | - |
| Q4 2020 | - | - | - |
| Q2 2020 | 1 | - | - |
| Q1 2020 | - | - | - |
| Q4 2019 | - | - | - |
| Q2 2019 | 9 | - | - |
| Q1 2019 | 1 | - | - |
| Q4 2018 | - | - | - |
| Q3 2018 | 1 | 2 | 50.00% |
As of Q4 2023, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Spyre Therapeutics's stocks.
Spyre Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| SNTI | Senti Biosciences, Inc. |
| DSGN | Design Therapeutics, Inc. |
| BLCM | Bellicum Pharmaceuticals, Inc. |
| ALRN | Aileron Therapeutics, Inc. |
| TIL | Instil Bio, Inc. |
| NUVB | Nuvation Bio Inc. |
| ELYM | Eliem Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| CING | Cingulate Inc. |
| EFTR | eFFECTOR Therapeutics, Inc. |
| CTMX | CytomX Therapeutics, Inc. |
| BPTH | Bio-Path Holdings, Inc. |
| LABP | Landos Biopharma, Inc. |
| HILS | Tharimmune, Inc. |
| IKNA | Ikena Oncology, Inc. |
| XLO | Xilio Therapeutics, Inc. |
| NLTX | Neurogene Inc. |
| ASMB | Assembly Biosciences, Inc. |
| CBIO | Gyre Therapeutics, Inc. |
| BNTC | Benitec Biopharma Inc. |
AGLE Ownership FAQ
Who Owns Spyre Therapeutics?
Spyre Therapeutics is owned by institutional shareholders (0.33%), insiders (2.40%), and public (97.26%). The largest institutional shareholder of Spyre Therapeutics is VR ADVISER, LLC (0% of total shares) and the top mutual fund owner is VANGUARD VALLEY FORGE FUNDS (0.07% of total shares).
Who are the major institutional shareholders of Spyre Therapeutics?
Spyre Therapeutics's major institutional shareholders are VR ADVISER, LLC, IFP ADVISORS, INC, and YU FAN. The top five shareholders own together 0% of the company's share outstanding.
How many Spyre Therapeutics shareholders are there?
As of Sep 2023, there are 3 institutional shareholders of Spyre Therapeutics.
What percentage of Spyre Therapeutics is owned by VR ADVISER, LLC?
VR ADVISER, LLC owns 0 shares of Spyre Therapeutics, representing 0% of the company's total shares outstanding, valued at $0 (as of Dec 2023).
What percentage of Spyre Therapeutics is owned by IFP ADVISORS, INC?
As of Dec 2023, IFP ADVISORS, INC holds 0 shares of Spyre Therapeutics (AGLE), compromising 0% of the company, valued at $0.
What percentage of Spyre Therapeutics is owned by YU FAN?
YU FAN is the third largest holder of Spyre Therapeutics. The company owns 0 of the company's shares outstanding (worth $0).